BioDlink International Company Limited (HKG:1875)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.050
-0.020 (-0.49%)
Mar 10, 2026, 4:08 PM HKT
99.51%
Market Cap 3.15B
Revenue (ttm) 1.17B
Net Income (ttm) 7.96M
Shares Out 772.79M
EPS (ttm) 0.01
PE Ratio 395.36
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 699,600
Average Volume 1,858,535
Open 4.050
Previous Close 4.070
Day's Range 4.020 - 4.080
52-Week Range 1.520 - 4.660
Beta 0.21
RSI 56.76
Earnings Date Mar 18, 2026

About HKG:1875

BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 604
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1875
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.